# Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

> **NCT04250116** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Yonsei University** · enrollment: 960 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** NOAC monotherapy
- **DRUG:** Dual antithrombotic therapy with NOAC and clopidogrel

## Key facts

- **NCT ID:** NCT04250116
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-04-28
- **Primary completion:** 2025-04
- **Final completion:** 2026-04
- **Target enrollment:** 960 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04250116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04250116, "Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04250116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*